Document is current
Any future updates will be listed below
-
Authors
Zhang, Zhenchao
Luo, Rui
Kelly, William K.
Chen, Joshua
Donahue, Shane
Ip, Kevan
Handley, Nathan R.
Tester, William J.
Tsang, Miranda L.
Kim, Felix J.
Myers, Ronald
Lu-Yao, Grace
Gu, Jian
Lin, Jianqing
Li, Bingshan
Wang, Chun http://orcid.org/0000-0002-3200-8977
Yang, Hushan http://orcid.org/0000-0001-9920-1731
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (R01CA255792, P20CA233255, R01CA255792, R01CA255792)
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute
- License Information
-
More Information
Article History
Received: 15 May 2023
Revised: 15 November 2023
Accepted: 17 November 2023
First Online: 6 December 2023
Competing interests
: HY is on the SAB of Oriomics Inc., a shareholder of Illumina, Pfizer, and Oriomics, and serves as a NIH study section reviewer. WKK is the consultant/SAB of Janssen, Bayer, and Merck-Sharpe Dome. The above reported activities were not related to the research reported in this article. All other authors did not report any competing interests related to the research reported in this article.
